NeurogesX Patch for HIV Pain Might Be Ineffective, FDA Says
This article is for subscribers only.
A pain patch from NeurogesX Inc., a specialty drugmaker that has never reported an annual profit, may not relieve pain related to nerve damage commonly associated with HIV, U.S. regulators said. The shares plunged 22 percent.
Food and Drug Administration staff raised questions in a report today about whether the prescription-strength capsaicin patch called Qutenza proved “substantial efficacy” in treating pain caused by neuropathy linked to the virus. Advisers to the agency are scheduled to meet Feb. 9 to discuss San Mateo, California-based NeurogesX’s patch.